Key facts
- Notable investors include FundWA.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Black Swan Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Black Swan Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Black Swan Biotech
Developer of antisense oligonucleotide therapeutics designed to treat motor neuron disease. The company focuses on developing gene-modulating therapies targeting genetic drivers of conditions such as amyotrophic lateral sclerosis, enabling advancement of precision-based treatment approaches.
- Sector
- Healthcare
- HQ
- Mount Pleasant, Australia
- Website
- blackswanbio.com/
- Ownership
- Privately Held (backing)
Black Swan Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Black Swan Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Black Swan Biotech in its N-PORT filings yet. We sweep new filings monthly.